A PCR method for VKORC1 G-1639A and CYP2C9 A1075C genotyping useful to warfarin therapy among Japanese by Takashi Tamura et al.
a SpringerOpen Journal
Tamura et al. SpringerPlus 2014, 3:499
http://www.springerplus.com/content/3/1/499METHODOLOGY Open AccessA PCR method for VKORC1 G-1639A and CYP2C9
A1075C genotyping useful to warfarin therapy
among Japanese
Takashi Tamura1*, Nobuyuki Katsuda2 and Nobuyuki Hamajima3Abstract
Warfarin is widely prescribed for patients with the risk of thromboembolism around the world. The inter-individual
and inter-racial differences in appropriate dosage depend highly on age, body weight, and genetic factors. A lot of
studies including genome-wide association studies revealed that vitamin K epoxide reductase complex, subunit 1
(VKORC1) G-1639A and Cytochrome P450 (CYP) 2C9 A1075C are the most strong genetic factors for determining
warfarin effects in Asians and Africans. Since we developed a quick and inexpensive genotyping method, polymerase
chain reaction with confronting two-pair primers (PCR-CTPP), the method was applied for these genotypes to examine
the possibility to clinical use. Subjects were 436 examinees (117 males and 319 females, aged 32 to 85 years) who
attended a health checkup program in Japan. The PCR-CTPP for VKORC1 G-1639A and CYP2C9 A1075C was conducted
for the subjects, as well as the samples genotyped by DigiTag2 method. The allele frequencies of VKORC1 G-1639A
were 0.085 for G and 0.915 for A, and those of CYP2C9 A1075C were 0.979 for A and 0.021 for C, being in
Hardy-Weinberg equilibrium (p = 0.658 and p = 0.514, respectively). These frequencies were similar to those
reported in the HapMap project. Genotyping for both SNPs by PCR-CTPP was replicated by DigiTag2 method.
Our results indicated that the PCR-CTPP could be one of the alternative methods for genotyping VKORC1 G-1639A and
CYP2C9 A1075C for Asians and Africans with similar allele frequencies to Japanese.
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Warfarin is one of the most widely prescribed anticoagu-
lants to prevent venous and arterial thromboembolism.
This medicine has a very narrow therapeutic range; the
high doses increase the risk of bleeding and the low
doses do not prevent thromboembolic disorders such as
stroke. It is well known that warfarin exhibits large
inter-individual and inter-racial differences in the dosage
for an appropriate effect. It needs a relatively long time
in practice to determine the appropriate dosage for each
patient within the optimal prothrombin time measured
with an international normalized ratio (PT-INR) range.
Warfarin exerts its anticoagulant effect by inhibiting vita-
min K epoxide reductase complex, subunit 1 (VKORC1)
(Zimmermann and Matschiner 1974; Suttie 1987). VKORC1* Correspondence: ttamura@gifu-u.ac.jp
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in any medium, provided the original work is precycles vitamin K 2,3-epoxide to vitamin K hydroquin-
one, which is essential for glutamyl carboxylation of clot-
ting factors II, VII, IX, and X (Nelsestuen et al. 1974;
Stenflo et al. 1974; Suttie 1987). Several studies have re-
ported that the rare mutations in VKORC1 gene brought
clotting factor deficiencies, resulting in warfarin resistance
(Li et al. 2004; Rost et al. 2004; D’Andrea et al. 2005).
Among them,VKORC1 G-1639A was identified as one of
the most strong causes for warfarin dose requirement
(Rieder et al. 2005; Yuan et al. 2005).
VKORC1 G-1639A is located at the promoter region of
VKORC1 gene (Yuan et al. 2005), and quantitatively chan-
ged the expression of VKORC1 protein (Rieder et al.
2005). The promoter with VKORC1 -1639G major allele
showed 44% increase in promoter activity compared with
the promoter with -1639A minor allele (Rieder et al.
2005). These findings have proved that VKORC1 G-1639A
is a single nucleotide polymorphism (SNP) to be one ofan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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ences in warfarin dosage.
Cytochrome P450 (CYP) is known to play an integral
role in biological oxygenation reactions for medicines.
CYP2C9 is one of the major isoforms of CYP family,
which metabolizes S-warfarin to 7-hydroxywarfarin and
6-hydroxywarfarin (Kaminsky and Zhang 1997). The hu-
man CYP2C9 gene is approximately 55 kb long and located
on chromosome 10q24.2 (Meehan et al. 1988; Goldstein
and de Morais 1994). Among the genetic variants reported
in the human CYP2C9 gene (Sim and Ingelman-Sundberg
2013), CYP2C9 *2 (rs1799853, c.430C > T, p.Arg144Cys)
and CYP2C9 *3 (rs1057910, c.1075A > C, p.Ile359Leu)
alleles are relatively frequent minor alleles in Caucasians,
influencing warfarin metabolism (Higashi et al. 2002).
CYP2C9 *1 allele distributes widely in any ethnic groups,
denoted as the wild type (Yin and Miyata 2007). For S-
warfarin to 7-hydroxylation, CYP2C9 enzyme activity with
*2 allele showed 50% reduction in Vmax (maximum vel-
ocity) and a higher Km (Michaelis constant) compared
with the wild type (Rettie et al. 1994; Sullivan-Klose et al.
1996; Yamazaki et al. 1998; Yin and Miyata 2007).
CYP2C9 *3 showed a more marked reduction of approxi-
mately 90% of the proper clearance (Vmax/Km) compared
with the wild type (Rettie et al. 1994; Sullivan-Klose et al.
1996; Yamazaki et al. 1998; Yin and Miyata 2007). These
reports show that CYP2C9 *2 and *3 variants are highly
implicated in warfarin metabolism (Aithal et al. 1999). Ac-
cording to the HapMap data, Asians and Africans have no
*2 of CYP2C9.
In line with these findings, genotyping both VKORC1
G-1639A and CYP2C9 *3 is considered to be useful to find
an appropriate individual warfarin dosage for Asians and
Africans. In August 2007, the Food and Drug Administra-
tion (FDA) in the United States actually approved revisions
of attached document for warfarin, following the reports of
effects of VKORC1 and CYP2C9 on dose requirements
(Vladutiu 2008). The FDA recommend that patients pos-
sessing these variants be considered to start from a lower
initial dose to avoid the risk of bleeding.
For genotyping, several methods have been reported
including polymerase chain reaction-restriction frag-
ments length polymorphism (PCR-RFLP) (Erlich et al.
1991), real-time PCR using TaqMan probes (De la Vega
et al. 2005), DNA microarray method (Nishida et al.
2007) and quenching probe method (Tani et al. 2009).
Each method has limitations, and time and costs for
genotyping vary among the methods. We have devel-
oped a quick and inexpensive genotyping method named
PCR with confronting two-pair primers (PCR-CTPP)
(Hamajima et al. 2000; Hamajima 2001), and applied it for
many SNPs. This paper describes the feasibility to geno-
type VKORC1 G-1639A and CYP2C9 *3 with the PCR-
CTPP for clinical warfarin use.Subjects and methods
Subjects
Study subjects were 436 examinees (117 males and 319 fe-
males, aged 32 to 85 years) who attended a health checkup
program supported by the Nagoya municipal government
in 2000. The examinees were inhabitants of Nishi ward at
Nagoya city in Japan. A written informed consent to an-
onymous uses of the residual blood for genetic tests as
well as information on demographic characteristics was
obtained when the health checkup. About 2 ml of blood
was left after a routine test for health check.
Among 489 examinees invited to the study, 468 (95.7%)
agreed to provide their residual blood for genetic tests and
related information. Three residual blood samples were
not available for DNA extraction. In addition, 29 extracted
buffy coat samples were used up for other genotyping in
previous studies (Hamajima et al. 2001; 2002; 2003). The
remaining 436 examinees were subjects in this study.
For both VKORC1 G-1639A and CYP2C9 A1075C, 436
examinees were tested by DigiTag2 method to confirm re-
sults of genotyping by PCR-CTPP. For CYP2C9 A1075C,
each of two subjects with *1*1, *1*3, and *3*3 among 5,017
participants (3,413 males and 1,604 females, aged 35 to
69 years) in Shizuoka area of the Japan Multi-Institutional
Collaborative Cohort Study (J-MICC Study) (Asai et al.
2009) were genotyped by PCR-CTPP in order to confirm
whether the genotype information are accorded with those
obtained by DigiTag2 method.
Genotyping
DNA for 436 health check examinees in this study was ex-
tracted from the buffy coat fraction preserved at −40°C by
a QIAamp DNA Blood Mini Kit (QIAGEN Inc., Valencia,
CA). The SNPs were genotyped by PCR-CTPP, and the
basic logic has been reported previously (Hamajima et al.
2000; Hamajima 2001). This method requires four primers
(two pairs) for each allele specific amplification; F1 and
R1 for X allele, and F2 and R2 for the Y allele (shown
in Figure 1). The end base of R1 and F2 should be the pos-
ition of SNP. The PCR amplifies three different-sized bands
of DNA; between F1 and R1, between F2 and R2, and be-
tween F1 and R2. The primer sequences for VKORC1
G-1639A and CYP2C9 A1075C were shown with the
melting temperatures estimated by base sequence algo-
rithm (Breslauer et al. 1986) in Table 1.
The PCR was performed with initial denaturation at
95°C for 10 min, followed by 30 cycles of denaturation
at 95°C for 1 min, annealing at 62°C for CYP2C9 A1075C
and at 61°C for VKORC1 G-1639A for 1 min, and exten-
sion at 72°C for 1 min. The final extension was at 72°C for
5 min.
On the other hand, DNA for participants in Shizuoka
area of the J-MICC Study was extracted from the buffy
coat fraction by BioRobot® M48 (QIAGEN group, Tokyo,
Figure 1 Logic of PCR-CTPP. a, size for X allele; b, size for Y allele; c = a + b - (d - 1), size between primers 1 F and 2R; d, Sum of the size of
primers 2 F and 1R. PCR-CTPP = Polymerase chain reaction with confronting two-pair primers.
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(NGK INSULATORS, Ltd., Nagoya, Japan) (Nishida
et al. 2007).
Results
Figure 2 shows actual gels for VKORC1 G-1639A (rs9923231)
in Gel (A) and CYP2C9 A1075C (rs1570910) in Gel (B)
obtained by PCR-CTPP. Each Sample (from one to six in
Figure 2) was different one. Among 436 subjects, there
was no one with *3*3 of CYP2C9 because of the less fre-
quency. We therefore selected the subjects with *3*3
among participants of Shizuoka area in the J-MICC Study
in order to genotyping by PCR-CTPP.Table 1 Primer sequences of PCR-CTPP for VKORC1 G-1639A a
Primers Sequences
VKORC1 G-1639A F1 5′ CAC AGA CGC C
VKORC1 G-1639A R1 5′ CGT GAG CCA C
VKORC1 G-1639A F2 5′ GAA GAC CTG A
VKORC1 G-1639A R2 5′ CTC AGC CTC CC
CYP2C9 A1075C F1 5′ CCA GGA AGA G
CYP2C9 A1075C R1 5′ TGG TGG GGA G
CYP2C9 A1075C F2 5′ GCA CGA GGT C
CYP2C9 A1075C R2 5′ GAG TTA TGC AC
CYP = Cytochrome P450, PCR-CTPP = Polymerase chain reaction with confronting tw
tase complex, subunit 1.
Polymorphic bases are indicated in bold type.The genotype information (*1*1, *1*3, and *3*3: each of
two samples) of Shizuoka area obtained by DigiTag2
method was accorded with that obtained by PCR-CTPP.
There was no genotype information for VKORC1 G-1639A
in Shizuoka area of the J-MICC Study. Both VKORC1
G-1639A and CYP2C9 A1075C for 436 examinees were
replicated by DigiTag2 method.
Table 2 shows the genotype frequencies of VKORC1
G-1639A and CYP2C9 A1075C. Each allele frequency
was all in Hardy-Weinberg equilibrium. As failed geno-
typing, there were 10 (2.3%, n = 436) for VKORC1 G-
1639A, and four (0.9%, n = 436) for CYP2C9 A1075C.
Comparisons between these allele frequencies and thosend CYP2C9 A1075C
Tm (°C)
AG AGG AAG AGA G 64.0
CG CAC CT 65.1
AA AAC AAC CAT TGG CCG 64.4
A AGT AGT TTG G 62.1
AT TGA ACG TGT GAT TG 61.6
AA GGT CAA T 61.3
CA GAG ATA CC 61.7
T TCT CTC ACC CG 61.1
o-pair primers, Tm = Melting temperature, VKORC1 = Vitamin K epoxide reduc-
Figure 2 Representative gels. (A) VKORC1 rs9923231 polymorphism. Lane M, a 100-bp ladder; lanes 1 and 2, an AA homozygote with fragments
of 119-bp and 284-bp; lanes 3 and 4, a GA heterozygote with fragments of 119-bp, 208-bp and 284-bp; and lanes 5 and 6, a GG with fragments
of 208-bp and 284-bp. (B) CYP2C9 rs1570910 polymorphism. Lane M, a 100-bp ladder; lanes 1 and 2, a *1*1 homozygote with fragments of
125-bp and 287-bp; lanes 3 and 4, a *1*3 heterozygote with fragments of 125-bp, 200-bp and 287-bp; and lanes 5 and 6, a *3*3 with fragments
of 200-bp and 287-bp. CYP = Cytochrome P450, VKORC1 = Vitamin K epoxide reductase complex, subunit 1.
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were shown in Table 3, which were all fairly similar.
Discussion
In this study, we finely conducted the genotyping for
VKORC1 G-1639A and CYP2C9 A1075C using PCR-
CTPP method. The allele frequencies were confirmed
to be reasonable by the comparisons with those re-
ported in the HapMap data. Both SNPs for 436 examineesTable 2 Genotypes and allele frequencies for VKORC1










GG 2 0.5 G 0.085 0.514






AA (*1*1) 414 95.8 *1 0.979 0.658
AC (*1*3) 18 4.2 *3 0.021
CC (*3*3) 0 0
Total b432 100
CYP = Cytochrome P450, PCR-CTPP = Polymerase chain reaction with confronting
two-pair primers, VKORC1 = Vitamin K epoxide reductase complex, subunit 1.
aData was missing for 10 subjects with unsuccessful genotyping.
bFour were failed.were replicated by DigiTag2 method. These results have
proved that PCR-CTPP is applicable for genotyping
VKORC1 G-1639A and CYP2C9 A1075C.
For genotyping SNPs, several studies have recommended
their options (Erlich et al. 1991; De la Vega et al. 2005;
Nishida et al. 2007; Tani et al. 2009). Among them, PCR-
RFLP and TaqMan method are commonly used. None-
theless, they were not necessarily confirmed to have the
feasibility or be reasonable for genotyping VKORC1
G-1639A and CYP2C9 *3 for tailored warfarin use. Be-
sides, former needs a longer time and later is quick with
expensiveness for genotyping.
The main difference between PCR-CTPP and PCR-
RFLP is that PCR-CTPP dose not need incubation with
restriction enzymes for PCR product digestion. PCR-
CTPP therefore has an advantage of lowest cost only forTable 3 Comparisons of allele frequencies for VKORC1
G-1639A and CYP2C9 A1075C
Allele frequency VKORC1 c.-1639G > A
(rs9923231)
CYP2C9 c.1075A > C
(rs1057910)
G A A C
Nagoya citizen 0.085 0.915 0.979 0.021
HapMap projects
African 0.978 0.022 1.000 0.000
Caucasian 0.602 0.398 0.942 0.058
Chinese 0.058 0.942 0.953 0.047
Japanese 0.099 0.901 0.977 0.023
Japanese in
Shizuoka area
Yoshizawa, et al. 2009 0.082 0.918 0.979 0.021
CYP = Cytochrome P450, VKORC1 = Vitamin K epoxide reductase complex, subunit 1.
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step in PCR-CTPP, which means that we could conduct
the genotyping only half of the time compared with
PCR-RFLP. Recently, use of real-time PCR was also de-
veloped for genotyping SNPs (De la Vega et al. 2005), al-
though the cost per one sample is still too expensive
(about two dollars), and the method needs exclusive ma-
chines in laboratory as in DigTag2 and Q-probe methods
(Nishida et al. 2007; Tani et al. 2009). In contrast, the
cost of PCR-CTPP is only half dollar per one sample (as
costs of primers and Taq polymerase).
Some technical problems have been reported for PCR-
CTPP (Hamajima et al. 2002). The strength of bands is
dependent on the balance in melting temperature of
each primer. Addition of one base to a primer changes
its melting temperature and causes distraction of the
balance of the bands strength. The melting temperatures
varied in a wide range (shown in Table 1). The optimum
primers and all the condition in this study were deter-
mined after several unsuccessful combinations. However,
a further option that one primer amplification of PCR-
CTPP products (OPA-CTPP) has been developed for re-
solving these problems (Yin et al. 2012).
As limitations, we could not verify the detection for *2 of
CYP2C9 because almost all Japanese have no *2 of CYP2C9
as well as other Asians and Africans. It needs to confirm
those with the *2 using PCR-CTPP for Caucasian. Add-
itionally, it may also need to confirm those with *5, *6, *8,
and *11 in relation to warfarin dose for Africans, when the
frequencies are considered to be high on the clinical prac-
tice (Limdi et al. 2008; Scott et al. 2009).
The proportions of failed genotyping seem to be rela-
tively high. These phenomena, however, would be ex-
plained by buffy condition (i.e., lowered concentration,
insufficient amount of sample, or DNA degradation over
time).
Using PCR-CTPP, we have already succeeded in other
tailored therapy and prevention. The details were de-
scribed elsewhere (Tamura et al. 2011, 2012). Tailored
warfarin therapy in clinical practice could also be sup-
ported by PCR-CTPP, especially among Japanese.
Conclusion
We suggested that PCR-CTPP would be useful when
genotyping VKORC1 G-1639A and CYP2C9 *3 is needed
in tailored warfarin use for Asians and Africans. Appli-
cation, experience, and further data in real patients
with warfarin therapy would be warranted hereafter.
Establishment in other tailored therapy is also
expected.
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